BIOXCEL THERAPEUTICS
5 recorded signal(s) across 1 type(s) · recorded between 2022-04-19 and 2026-08-31
Each entry below describes what a public filing records, on the date it was recorded. This page ranks nothing and predicts nothing. Where the product does score, it scores the SEVERITY OF A DISCLOSED SIGNAL — deterministic, explicable, and never a probability of default.
SEC cross-link: ticker BTAI · SEC CIK 0001720893 (linked as of 2026-07-12)
BIOXCEL THERAPEUTICS, INC. recorded a security interest over 1 patent to OAKTREE FUND ADMINISTRATION, LLC, recorded 2026-08-31.
confidence 0.95 · as of 2026-08-31 · detail · view patent
unknown · as of 30 Jan 2024 — Release status unknown — no release has been observed for this security interest (releases observed only up to 30 Jan 2024).
BIOXCEL THERAPEUTICS, INC. recorded a security interest over 1 patent to OAKTREE FUND ADMINISTRATION, LLC, recorded 2026-06-23.
confidence 0.95 · as of 2026-06-23 · detail · view patent
unknown · as of 30 Jan 2024 — Release status unknown — no release has been observed for this security interest (releases observed only up to 30 Jan 2024).
BIOXCEL THERAPEUTICS, INC. recorded a security interest over 1 patent to OAKTREE FUND ADMINISTRATION, LLC, recorded 2024-09-11.
confidence 0.95 · as of 2024-09-11 · detail · view patent
unknown · as of 30 Jan 2024 — Release status unknown — no release has been observed for this security interest (releases observed only up to 30 Jan 2024).
BIOXCEL THERAPEUTICS, INC. recorded a security interest over 8 patents to OAKTREE FUND ADMINISTRATION, LLC, recorded 2022-04-19.
confidence 0.95 · as of 2022-04-19 · detail · view patent
active · as of 30 Jan 2024 — No release observed as of 30 Jan 2024 (release coverage ends 30 Jan 2024).
BIOXCEL THERAPEUTICS, INC. recorded a security interest over 8 patents to OAKTREE FUND ADMINISTRATION, LLC, recorded 2022-04-19.
confidence 0.95 · as of 2022-04-19 · detail · view patent
active · as of 30 Jan 2024 — No release observed as of 30 Jan 2024 (release coverage ends 30 Jan 2024).